PDF 3799.pdf | Request a copy Full text restricted

Abstract

Objective. Transplantation of hematopoietic progenitor stem cells (HPC) is an important treatment modality for a variety of neoplastic diseases. HPC collection for transplantation with granulocyte colony-stimulating factor may be unsuccessful in patients who have received prior chemotherapy or for other reasons. Methods to improve mobilization of HPCs are required. Disruption of the interaction between the cell surface receptor CXCR4 and its ligand stromal derived factor-1 (SDF-1) is a mechanism for HPC release from the bone marrow into the peripheral blood (PB).

Methods. We carried out a clinical trial to evaluate the effects of ingestion of a fucoidan, galactofucan sulfate (a putative HPC mobilizing agent) on circulating CD34+ cells, CXCR4 expression, and levels of SDF-1, interferon gamma (IFN-g) and interleukin 12.

Results. Following ingestion of fucoidan, CD34+ cells increased significantly in the PB from 1.64 to 1.84 cells/mL after 4 days. The proportion of CD34+ cells that expressed CXCR4 increased from 45 to 90% after 12 days, the plasma level of SDF-1 increased from 1978 to 2010 pg/mL, and IFN-g level increased from 9.04 to 9.89 pg/mL.

Conclusion. Oral fucoidan significantly amplified the CXCR4+ HPC population. The ability to mobilize HPC using sulfated polysaccharides and mobilize more HPC with high levels of CXCR4 could be clinically valuable.

Item Type:	Article
Authors/Creators:	Irhimeh, M and Fitton, H and Lowenthal, RM
Journal or Publication Title:	Experimental Hematology
Publisher:	ELSEVIER SCIENCE INC
ISSN:	0301-472X
DOI / ID Number:	10.1016/j.exphem.2007.02.009
Additional Information:	© 2007 International Society for Experimental Hematology. The definitive version is available at http://www.sciencedirect.com
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page